Jun 17, 2024
Keros Therapeutics Announces Leadership Updates
Jun 17, 2024
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
Jun 04, 2024
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
Jun 03, 2024
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
May 28, 2024
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
May 14, 2024
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
May 08, 2024
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Mar 14, 2024
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
Mar 05, 2024
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
Feb 28, 2024
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Investor Contact